Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity

Arch Ophthalmol. 2012 Jun;130(6):801-2. doi: 10.1001/archophthalmol.2011.1802.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Disease Progression
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight
  • Infant, Newborn
  • Intravitreal Injections
  • Recurrence
  • Retinal Detachment / diagnostic imaging
  • Retinopathy of Prematurity / drug therapy*
  • Treatment Failure
  • Ultrasonography
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab